Three questions may help distinguish stress, urge incontinence

Article

A three-question, noninvasive test appears to accurately classify stress and urge incontinence, according to a study in the Annals of Internal Medicine (2006; 144:715-23).

A three-question, noninvasive test appears to accurately classify stress and urge incontinence, according to a study in the Annals of Internal Medicine (2006; 144:715-23).

The multicenter study enrolled 301 women (mean age, 56 years) with untreated incontinence for an average of 7 years and a range of incontinence severity. The women answered three incontinence questions that comprise the 3IQ test and then responded to an extended evaluation to determine urge or stress incontinence.

The responses to the three questions were compared with responses of the extended evaluation, which was considered the gold standard. When classifying urge incontinence, the 3IQ questionnaire had a sensitivity of .75 (95% CI, .68-.81), specificity of .77 (CI, .69-.84), and a positive likelihood ratio of 3.29 (CI, 2.39 to 4.51). When classifying stress incontinence, the questionnaire had a sensitivity of .86 (CI, .79-.90), specificity of .60 (CI, .51-.68), and a positive likelihood ratio of 2.13 (CI 1.71-2.66).

Researchers, led by Jeannette S. Brown, MD, of the University of California, San Francisco, acknowledged that similar studies are needed in other populations, and clinical trials are needed to compare the outcomes of treatments based on the three-question test and the extended evaluation.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
© 2024 MJH Life Sciences

All rights reserved.